Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase II trial of autologous vaccines consisting of adjuvant GM-CSF plus proliferating tumor cells versus GM-CSF plus dendritic cells loaded with proliferating tumor cells in patients with metastatic melanoma (MAC-VAC)

X
Trial Profile

Randomized phase II trial of autologous vaccines consisting of adjuvant GM-CSF plus proliferating tumor cells versus GM-CSF plus dendritic cells loaded with proliferating tumor cells in patients with metastatic melanoma (MAC-VAC)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eltrapuldencel-T (Primary) ; Sargramostim
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms MAC-VAC
  • Most Recent Events

    • 23 Apr 2020 According to an AiVita Biomedical media release, results from this study were published in the Journal of Translational Medicine.
    • 04 Jun 2019 Results assessing survival for melanoma patients who were treated with patient specific vaccines by using data from two phase II studies presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Jun 2019 Pooled data from this and other trial (NCT00436930) were presented in an AiVita Biomedical Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top